

**Table 3.** Utility parameters.

<b>Health state</b>	<b>Value</b>	<b>Distribution</b>		<b>Source</b>	
NED (after primary treatment)	0.85	Beta	$\alpha=1337.1$	$\beta=236.0$	HETeCo trial*; [198]
Salvageable recurrence (surgery)	0.57	Beta	$\alpha=348.7$	$\beta=263.1$	[354]
Salvageable recurrence (re-irradiation)	0.57	Beta	$\alpha=348.7$	$\beta=263.1$	[354]
NED (after salvage surgery)	0.62	Beta	$\alpha=22.2$	$\beta=13.6$	[365]
NED (after re-irradiation)	0.62	Beta	$\alpha=22.2$	$\beta=13.6$	Assumption
Non-salvageable recurrence (chemotherapy/palliative care)	0.34	Beta	$\alpha=190.4$	$\beta=369.6$	[354]
Death	0.00	Fixed			

\* HETeCo trial preliminary data (n=60 patients). HETeCo: Health and Economic Outcomes of Two Different Follow up Strategies in Effectively Cured Advanced Head and Neck Cancer; NED: no evidence of disease.